{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:25:56Z","timestamp":1781108756623,"version":"3.54.1"},"reference-count":46,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Int"],"DOI":"10.3892\/mi.2023.85","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T07:09:14Z","timestamp":1683184154000},"source":"Crossref","is-referenced-by-count":6,"title":["HIPEC for gynaecological malignancies: A last update (Review)"],"prefix":"10.3892","volume":"3","author":[{"given":"Chrysoula","family":"Margioula\u2011Siarkou","sequence":"first","affiliation":[{"name":"2nd Department of Obstetrics and Gynaecology, Gynaecologic Oncology Unit, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristarchos","family":"Almperis","sequence":"additional","affiliation":[{"name":"2nd Department of Obstetrics and Gynaecology, Gynaecologic Oncology Unit, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexios","family":"Papanikolaou","sequence":"additional","affiliation":[{"name":"2nd Department of Obstetrics and Gynaecology, Gynaecologic Oncology Unit, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Simone","family":"Lagana","sequence":"additional","affiliation":[{"name":"Unit of Gynecologic Oncology, ARNAS \u2018Civico\u2011Di Cristina\u2011Benfratelli\u2019, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, I\u201190121 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Mavromatidis","sequence":"additional","affiliation":[{"name":"2nd Department of Obstetrics and Gynaecology, Gynaecologic Oncology Unit, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Guyon","sequence":"additional","affiliation":[{"name":"Gynaeocologic Oncology Unit Institute Bergonie, 33076 Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Dinas","sequence":"additional","affiliation":[{"name":"2nd Department of Obstetrics and Gynaecology, Gynaecologic Oncology Unit, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatios","family":"Petousis","sequence":"additional","affiliation":[{"name":"2nd Department of Obstetrics and Gynaecology, Gynaecologic Oncology Unit, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"key":"key20230627100320_b1-MI-3-3-00085","article-title":"Management of peritoneal metastases-cytoreductive surgery, HIPEC and beyond","author":"Rajan","year":"2018","journal-title":"Springer"},{"key":"key20230627100320_b2-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/annonc\/mdl428","article-title":"A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma","volume":"18","author":"Yan","year":"2007","journal-title":"Ann Oncol"},{"key":"key20230627100320_b3-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1080\/02656736.2017.1301576","article-title":"Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: Results from a worldwide analysis issue of the peritoneal surface oncology group international (PSOGI)","volume":"33","author":"Go\u00e9r\u00e9","year":"2017","journal-title":"Int J Hyperthermia"},{"key":"key20230627100320_b4-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1097\/IGC.0000000000000664","article-title":"Heated IntraPEritoneal chemotherapy (HIPEC) for patients with recurrent ovarian cancer: A systematic literature review","volume":"26","author":"Hotouras","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"key20230627100320_b5-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.suronc.2018.05.006","article-title":"HIPEC in patients with primary advanced ovarian cancer: Is there a role? A systematic review of short- and long-term outcomes","volume":"27","author":"Kireeva","year":"2018","journal-title":"Surg Oncol"},{"key":"key20230627100320_b6-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jviscsurg.2015.11.010","article-title":"Peritoneal carcinomatosis from unusual cancer origins: Is there a role for hyperthermic intraperitoneal chemotherapy?","volume":"153","author":"Honor\u00e9","year":"2016","journal-title":"J Visc Surg"},{"key":"key20230627100320_b7-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.2174\/138161212802002616","article-title":"Survival benefit of adding hyperthermic IntraPEritoneal chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: Review of evidence","volume":"18","author":"Mulier","year":"2012","journal-title":"Curr Pharm Des"},{"key":"key20230627100320_b8-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ygyno.2007.03.019","article-title":"Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery","volume":"106","author":"Bae","year":"2007","journal-title":"Gynecol Oncol"},{"key":"key20230627100320_b9-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ygyno.2011.05.004","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase-II trial","volume":"122","author":"Deraco","year":"2011","journal-title":"Gynecol Oncol"},{"key":"key20230627100320_b10-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"key":"key20230627100320_b11-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","article-title":"Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm","volume":"114","author":"Chi","year":"2009","journal-title":"Gynecol Oncol"},{"key":"key20230627100320_b12-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"key20230627100320_b13-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/s0090-8258(03)00278-6","article-title":"Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: A prospective study","volume":"90","author":"Eisenkop","year":"2003","journal-title":"Gynecol Oncol"},{"key":"key20230627100320_b14-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","article-title":"Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: A randomized clinical trial","volume":"157","author":"Lim","year":"2022","journal-title":"JAMA Surg"},{"key":"key20230627100320_b15-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N Engl J Med"},{"key":"key20230627100320_b16-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1245\/s10434-021-11087-7","article-title":"Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: A Phase 3 clinical trial","volume":"29","author":"Antonio","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"key20230627100320_b17-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejso.2019.05.006","article-title":"Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer","volume":"47","author":"Koole","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"key20230627100320_b18-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1200\/JCO.19.00594","article-title":"Cost effectiveness of interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in stage III ovarian cancer on the basis of a randomized phase III trial","volume":"37","author":"Koole","year":"2019","journal-title":"J Clin Oncol"},{"issue":"100098","key":"key20230627100320_b19-MI-3-3-00085","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100098","article-title":"Rationale and study design of the CHIPPI-1808 trial: A phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery","volume":"6","author":"El Hajj","year":"2021","journal-title":"ESMO Open"},{"key":"key20230627100320_b20-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1136\/ijgc-2020-001231","article-title":"Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial","volume":"30","author":"Koole","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"key20230627100320_b21-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: A prospective randomized phase III study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"key20230627100320_b22-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1200\/JCO.21.00605","article-title":"Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: An MSK team ovary phase II study","volume":"39","author":"Zivanovic","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20230627100320_b23-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1002\/cncr.29054","article-title":"Site-specific factors for cancer of the corpus uteri from SEER registries: Collaborative stage data collection system, version 1 and version 2","volume":"120","author":"Jamison","year":"2014","journal-title":"Cancer"},{"key":"key20230627100320_b24-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10585-019-09970-5","article-title":"Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for endometrial cancer-derived peritoneal metastases: A systematic review","volume":"36","author":"Tempfer","year":"2019","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"key20230627100320_b25-MI-3-3-00085","doi-asserted-by":"publisher","DOI":"10.1186\/s12893-021-01449-z","article-title":"Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: A multi-institutional study from PSOGI and BIG RENAPE groups","volume":"22","author":"Gomes David","year":"2022","journal-title":"BMC Surg"},{"key":"key20230627100320_b26-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.ejso.2021.10.013","article-title":"Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal sarcomatosis-A systematic review and meta-analysis","volume":"48","author":"Wong","year":"2022","journal-title":"Eur J Surg Oncol"},{"key":"key20230627100320_b27-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/SLA.0b013e3181928f2f","article-title":"Multifocality in retroperitoneal sarcoma: A prognostic factor critical to surgical decision-making","volume":"249","author":"Anaya","year":"2009","journal-title":"Ann Surg"},{"key":"key20230627100320_b28-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1002\/cncr.10504","article-title":"Tumor volume as a prognostic factor for sarcomatosis","volume":"94","author":"Bilimoria","year":"2002","journal-title":"Cancer"},{"issue":"11795549211065308","key":"key20230627100320_b29-MI-3-3-00085","doi-asserted-by":"publisher","DOI":"10.1177\/11795549211065308","article-title":"Is cytoreductive surgery possible in cervical cancer peritoneal carcinomatosis?","volume":"15","author":"Duzgun","year":"2021","journal-title":"Clin Med Insights Oncol"},{"issue":"100909","key":"key20230627100320_b30-MI-3-3-00085","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2021.100909","article-title":"Management of recurrent cervical cancer with peritoneal carcinomatosis with HIPEC","volume":"39","author":"Lantsman","year":"2021","journal-title":"Gynecol Oncol Rep"},{"key":"key20230627100320_b31-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.1245\/s10434-020-08843-6","article-title":"Implications of postoperative complications for survival after cytoreductive surgery and HIPEC: A multi-institutional analysis of the US HIPEC collaborative","volume":"27","author":"Gamboa","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"105669","key":"key20230627100320_b32-MI-3-3-00085","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2021.105669","article-title":"Survival of large volume recurrent endometrial cancer with peritoneal metastases treated by cytoreductive surgery, HIPEC and EPIC. Report of a case","volume":"80","author":"Sugarbaker","year":"2021","journal-title":"Int J Surg Case Rep"},{"key":"key20230627100320_b33-MI-3-3-00085","first-page":"3019","article-title":"Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin","volume":"23","author":"de Bree","year":"2003","journal-title":"Anticancer Res"},{"key":"key20230627100320_b34-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.3747\/co.19.944","article-title":"Multidisciplinary management of cancer patients: Chasing a shadow or real value? An overview of the literature","volume":"19","author":"Croke","year":"2012","journal-title":"Curr Oncol"},{"key":"key20230627100320_b35-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"9363","DOI":"10.2147\/CMAR.S220976","article-title":"Benefits and limitations of a multidisciplinary approach in cancer patient management","volume":"12","author":"Berardi","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"53","key":"key20230627100320_b36-MI-3-3-00085","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2021.5233","article-title":"A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (review)","volume":"59","author":"Falzone","year":"2021","journal-title":"Int J Oncol"},{"key":"key20230627100320_b37-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.ygyno.2017.01.017","article-title":"Multidisciplinary approach in the management of advanced ovarian cancer patients: A personalized approach. Results from a specialized ovarian cancer unit","volume":"144","author":"Aletti","year":"2017","journal-title":"Gynecol Oncol"},{"key":"key20230627100320_b38-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"9098","DOI":"10.1245\/s10434-021-10193-w","article-title":"HIPEC methodology and regimens: The need for an expert consensus","volume":"28","author":"Bhatt","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"e1007752","key":"key20230627100320_b39-MI-3-3-00085","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1007752","article-title":"BRCA challenge: BRCA exchange as a global resource for variants in BRCA1 and BRCA2","volume":"14","author":"Cline","year":"2018","journal-title":"PLoS Genet"},{"issue":"9","key":"key20230627100320_b40-MI-3-3-00085","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-019-0484-6","article-title":"Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status","volume":"12","author":"Gadducci","year":"2019","journal-title":"J Ovarian Res"},{"issue":"58","key":"key20230627100320_b41-MI-3-3-00085","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2022.5349","article-title":"Identification of the most common BRCA alterations through analysis of germline mutation databases: Is droplet digital PCR an additional strategy for the assessment of such alterations in breast and ovarian cancer families?","volume":"60","author":"Lavoro","year":"2022","journal-title":"Int J Oncol"},{"issue":"416","key":"key20230627100320_b42-MI-3-3-00085","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030416","article-title":"Tailoring ovarian cancer treatment: implications of BRCA1\/2 mutations","volume":"11","author":"Madariaga","year":"2019","journal-title":"Cancers (Basel)"},{"key":"key20230627100320_b43-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/jso.23688","article-title":"Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients-a case-control study","volume":"110","author":"Safra","year":"2014","journal-title":"J Surg Oncol"},{"key":"key20230627100320_b44-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20230627100320_b45-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ygyno.2012.11.038","article-title":"Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: A gynecologic oncology group study","volume":"128","author":"Monk","year":"2013","journal-title":"Gynecol Oncol"},{"key":"key20230627100320_b46-MI-3-3-00085","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1200\/JCO.18.01568","article-title":"Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG oncology\/gynecologic oncology group study","volume":"37","author":"Walker","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Medicine International"],"original-title":[],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T10:06:01Z","timestamp":1687860361000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mi.2023.85"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,5,4]]}},"URL":"https:\/\/doi.org\/10.3892\/mi.2023.85","relation":{},"ISSN":["2754-3242","2754-1304"],"issn-type":[{"value":"2754-3242","type":"print"},{"value":"2754-1304","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,4]]},"article-number":"25"}}